C3 Glomerulopathy

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS approval · 2025-11-06
Clinical Trial Update: C3G/Primary IC-MPGN EAP
Apellis' pegylated C3 inhibitor pegcetacoplan has gained marketing approval for C3 glomerulopathy and immune complex–mediated MPGN as part o…